Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review
Journal of Clinical Medicine · 17.07.2026 · 15 (14) · 5617
DOI: 10.3390/jcm15145617 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.07.2026. Verfasst von Aleksandra Złotowska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Student Scientific Association at the Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University…. Die Arbeit nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The alarming increase in the number of new bacterial defense mechanisms is exacerbating the problem of antibiotic resistance and poses a serious obstacle to the treatment of bacterial infections. Despite the approval of numerous new antibiotics by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), mainly from the beta-lactam group since 2000, only some of them possess unique mechanisms of action and activity against multidrug-resistant Gram-negative bacilli (MDR GNB), including carbapenem resistance. Eravacycline (EVT), formerly known as TP-434, is a newly developed non-beta-lactam, fully synthetic tetracycline derivative, approved for the treatment of complicated intra-abdominal infections (cIAIs) in adults.
Results
The analysis demonstrated significant efficacy of EVT across a wide range of in vitro and in vivo studies against MDR GNB, including carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE) and Gram-positive vancomycine-resistant pathogens.
Conclusions
The broad spectrum of activity and favorable safety profile of EVT are well-documented in the treatment of critically ill patients. However, its efficacy against clinically relevant Gram-negative bacteria varies depending on specific species and resistance phenotypes, particularly among carbapenem-resistant and extensively drug-resistant (XDR) isolates.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Student Scientific Association at the Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland.
- Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland.
ORCID-Profile: Aleksandra Złotowska, Julia Kacer, Mateusz Dudek, Wiesława Duszyńska
Zitieren
APA
Złotowska, A., Kacer, J., Dybko, Z., Dudek, M., & Duszyńska, W. (2026). Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review. Journal of Clinical Medicine, 15(14), 5617. https://doi.org/10.3390/jcm15145617
Vancouver
Złotowska A, Kacer J, Dybko Z, Dudek M, Duszyńska W. Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review. Journal of Clinical Medicine. 2026;15(14):5617. doi:10.3390/jcm15145617
BibTeX
@article{Zotowska2026,
author = {Złotowska, Aleksandra and Kacer, Julia and Dybko, Zuzanna and Dudek, Mateusz and Duszyńska, Wiesława},
title = {Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {14},
pages = {5617},
doi = {10.3390/jcm15145617}
}
EUVIMED